GREENLAND MINES LTD Increase (Decrease) in Accrued Liabilities
GREENLAND MINES LTD (GRML) reported Increase (Decrease) in Accrued Liabilities of $181.30 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-17.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-17
- GREENLAND MINES LTD increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was $105.37K.
- GREENLAND MINES LTD increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was $75.93K.
- GREENLAND MINES LTD increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was -$25.83K, a 105.10% decline year-over-year.
- GREENLAND MINES LTD increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was $7.66K, a 97.53% decline year-over-year.
- GREENLAND MINES LTD increase (decrease) in accrued liabilities for fiscal 2025 was -$879.94K, a 182.66% decline from fiscal 2024.
- GREENLAND MINES LTD increase (decrease) in accrued liabilities for fiscal 2024 was $1.06M.
- GREENLAND MINES LTD increase (decrease) in accrued liabilities for fiscal 2023 was -$2.28K, a 101.63% decline from fiscal 2022.
- GREENLAND MINES LTD increase (decrease) in accrued liabilities for fiscal 2022 was $140.37K.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 6 month as first filed | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 9 month as first filed | Increase (Decrease) in Accrued Liabilities 12 month | Increase (Decrease) in Accrued Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $105.37K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-08-17 | $181.30K 10-Q · filed 2026-08-17 | $155.47K derived: sum of 3 quarters · filed 2026-08-17 | $163.13K derived: sum of 4 quarters · filed 2026-08-17 | |||
| 2026-03-31 | $75.93K 10-Q/A · filed 2026-08-14 | $50.10K derived: sum of 2 quarters · filed 2026-08-14 | $57.76K derived: sum of 3 quarters · filed 2026-08-14 | -$372.93K derived: sum of 4 quarters · filed 2026-08-17 | |||
| 2025-12-31 | -$25.83K derived: 10-K/A 12 month − 10-Q 9 month · filed 2026-08-14 | -$18.17K derived: sum of 2 quarters · filed 2026-08-14 | -$448.86K derived: sum of 3 quarters · filed 2026-08-17 | -$879.94K 10-K/A · filed 2026-08-14 | |||
| 2025-09-30 | $7.66K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$423.03K derived: sum of 2 quarters · filed 2026-08-17 | -$854.11K 10-Q · filed 2025-11-13 | -$347.48K derived: sum of 4 quarters · filed 2026-08-17 | |||
| 2025-06-30 | -$430.69K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-08-17 | -$861.76K 10-Q · filed 2026-08-17 | -$355.14K derived: sum of 3 quarters · filed 2026-08-17 | -$45.24K derived: sum of 4 quarters · filed 2026-08-17 | |||
| 2025-03-31 | -$431.08K 10-Q/A · filed 2026-08-14 | $75.55K derived: sum of 2 quarters · filed 2026-08-14 | $385.45K derived: sum of 3 quarters · filed 2026-08-14 | $562.14K derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2024-12-31 | $506.63K derived: 10-K/A 12 month − 10-Q 9 month · filed 2026-08-14 | $816.52K derived: sum of 2 quarters · filed 2026-08-14 | $993.22K derived: sum of 3 quarters · filed 2026-08-14 | $1.06M 10-K/A · filed 2026-08-14 | |||
| 2024-09-30 | $309.90K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $486.59K derived: sum of 2 quarters · filed 2025-11-13 | $557.84K 10-Q · filed 2025-11-13 | $534.33K derived: sum of 4 quarters · filed 2025-11-13 | |||
| 2024-06-30 | $176.69K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-18 | $247.94K 10-Q · filed 2025-08-18 | $224.43K derived: sum of 3 quarters · filed 2025-08-18 | $243.27K derived: sum of 4 quarters · filed 2025-08-18 | |||
| 2024-03-31 | $71.25K 10-Q · filed 2024-05-23 | $47.74K derived: sum of 2 quarters · filed 2025-03-31 | $66.58K derived: sum of 3 quarters · filed 2025-03-31 | -$97.39K derived: sum of 4 quarters · filed 2025-03-31 | |||
| 2023-12-31 | -$23.51K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$4.67K derived: sum of 2 quarters · filed 2025-03-31 | -$168.64K derived: sum of 3 quarters · filed 2025-03-31 | -$2.28K 10-K · filed 2025-03-31 | $256.30K 10-K · filed 2024-04-17 | ||
| 2023-09-30 | $18.84K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-19 | -$145.13K derived: sum of 2 quarters · filed 2024-11-19 | $21.22K 10-Q · filed 2024-11-19 | $187.27K 10-Q · filed 2023-11-17 | $101.59K derived: sum of 4 quarters · filed 2024-11-19 | ||
| 2023-06-30 | -$163.97K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-19 | $2.39K 10-Q · filed 2024-08-19 | $133.15K 10-Q · filed 2023-08-21 | $82.76K derived: sum of 3 quarters · filed 2024-08-19 | $112.76K derived: sum of 4 quarters · filed 2024-08-19 | ||
| 2023-03-31 | $166.35K 10-Q · filed 2024-05-23 | $246.72K derived: sum of 2 quarters · filed 2024-05-23 | $276.72K derived: sum of 3 quarters · filed 2024-05-23 | $266.22K derived: sum of 4 quarters · filed 2024-05-23 | |||
| 2022-12-31 | $80.37K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-17 | $110.37K derived: sum of 2 quarters · filed 2024-04-17 | $99.87K derived: sum of 3 quarters · filed 2024-04-17 | $140.37K 10-K · filed 2024-04-17 | |||
| 2022-09-30 | $30.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-17 | $19.50K derived: sum of 2 quarters · filed 2023-11-17 | $60.00K 10-Q · filed 2023-11-17 | ||||
| 2022-06-30 | -$10.50K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-21 | $30.00K 10-Q · filed 2023-08-21 | |||||
| 2022-03-31 | $40.50K 10-Q · filed 2023-05-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |